Recent guidelines set forth by an interdisciplinary panel assembled by the American Thoracic Society sought to demystify primary ciliary dyskinesia and address 4 main diagnostic questions.
Measures of reversibility are of limited value for distinguishing smoke-related chronic obstructive pulmonary disease from asthma, but bronchodilator response testing may be a phenotypic marker for asthma.
Visual scoring of emphysema is predictive of an individual’s risk for lung cancer, with the centrilobular emphysema phenotype associated with the greatest risk.
Researchers have proposed a potentially useful way to categorize chronic obstructive pulmonary disease at diagnosis based on the classification of specific subtypes, according to a combination of visual and quantitative CT parameters.
The board of directors of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recently published an editorial urging more serious action should be taken to better manage chronic obstructive pulmonary disease.
The NDA for the investigational therapy elexacaftor (VX-445), for use in combination with tezacaftor and ivacaftor in the treatment of cystic fibrosis, has been submitted to the FDA.
